Key result
Six months after starting continuous ambulatory peritoneal dialysis, patients exhibited significant increases in multiple lipidomic species, including free fatty acids and ceramides, despite no changes in classical lipid markers.
Why the study?
Patients on peritoneal dialysis have increased cardiovascular disease risk and atherogenic lipid profiles, but classical lipid-lowering outcomes seen in the general population have not translated to peritoneal dialysis patients.
Does starting continuous ambulatory peritoneal dialysis alter the lipidomic profile in CKD patients?
Observational (n=39)
No
Does starting continuous ambulatory peritoneal dialysis alter the lipidomic profile in CKD patients?
Answers are grounded in this paper and cite their sources.
Patients starting peritoneal dialysis develop an atherogenic lipidomic profile beyond classical dyslipidemia markers, potentially explaining their increased cardiovascular risk.
Patients on peritoneal dialysis (PD) have an increased risk of cardiovascular disease (CVD) and an atherogenic lipid profile generated by exposure to high glucose dialysis solutions. In the general population, the reduction of classic lipids biomarkers is associated with improved clinical outcomes; however, the same results have not been seen in PD population, a lack of data this study aims to fulfill. Single-center prospective observational study of a cohort of CKD patients who started renal replacement therapy with continuous ambulatory peritoneal dialysis. The differences in the lipid profile and analytical variables before and 6 months after the start of peritoneal dialysis were analyzed. Samples were analyzed on an Ultra-Performance Liquid Chromatography system. Thirty-nine patients were enrolled in this study. Their mean age was 57.9 ± 16.3 years. A total of 157 endogenous lipid species of 11 lipid subclasses were identified. There were significant increases in total free fatty acids (p < 0.05), diacylglycerides (p < 0.01), triacylglycerides, (p < 0.01), phosphatidylcholines (p < 0.01), phosphatidylethanolamines (p < 0.01), ceramides (p < 0.01), sphingomyelins (p < 0.01), and cholesterol esters (p < 0.01) from baseline to 6 months. However, there were no differences in the classical lipid markers, neither lysophosphatidylcholines, monoacylglycerides, and sphingosine levels. 6 months after the start of the technique, PD patients present changes in the lipidomic profile beyond the classic markers of dyslipidemia.
No takes yet. Share an insight, caveat, or question.
Lluesa et al. (2022) conducted an observational in End-stage chronic kidney disease (n=39). Continuous ambulatory peritoneal dialysis vs. Baseline (before starting peritoneal dialysis) was evaluated on Changes in lipidomic profile from baseline to 6 months (p=<0.05). Six months after starting continuous ambulatory peritoneal dialysis, patients exhibited significant increases in multiple lipidomic species, including free fatty acids and ceramides, despite no changes in classical lipid markers.
Synapse has enriched 10 related papers. Consider them for comparative context: